Description:
Discover the dynamic landscape of the U.S. IVD market with Kalorama Information’s latest comprehensive report, United States Market for In Vitro Diagnostic (IVD) Tests, 4th Edition. As the dominant force in the global IVD industry, the U.S. market continues to evolve, facing numerous challenges and opportunities in a highly complex healthcare system.
Report Highlights:
- Market Overview:
- The U.S. IVD market remains the core geographical market in the world, leading the industry with its size and influence.
- Despite its dominance, the market is in a state of flux, managing a myriad of issues including an aging population and the lingering impact of COVID-19.
- In-Depth Market Segmentation:
- Detailed analysis of various IVD market segments in the United States, including:
- Clinical Chemistry
- Traditional Microbiology – Identification and Antibiotic Susceptibility Testing (ID/AST)
- Molecular Microbiology – Infectious Disease
- Point-of-Care (POC) Tests – Diabetes
- Point-of-Care (POC) Tests – All Other
- Immunoassays – Infectious Disease (non-POC)
- Immunoassays – Other
- Molecular Diagnostics – Non-infectious Disease
- Hematology
- Coagulation (non-POC)
- Histology
- Blood Testing and Typing
- Other IVD Segments
- Detailed analysis of various IVD market segments in the United States, including:
- Industry Trends and Drivers:
- Exploration of key trends shaping the present and future of the U.S. IVD market, such as:
- The aging population and its impact on healthcare demand.
- The lasting effects of the COVID-19 pandemic on IVD market growth and the increased need for testing.
- Exploration of key trends shaping the present and future of the U.S. IVD market, such as:
Top Company Profiles:
- Leading Players:
- Profiles of top companies in the U.S. IVD market, highlighting notable corporate events and recent developments.
- Insight into the strategies and innovations of industry leaders driving the market forward.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: U.S. IVD Market, by Segment, 2022-2027 (in millions $)
| Segment | 2022 | 2027 | CAGR |
| Clinical Chemistry | $XX Million | $XX Million | XX% |
| Microbiology – ID/AST | $XX Million | $XX Million | XX% |
| Molecular | $XX Million | $XX Million | XX% |
| Molecular Infectious Disease (with NAT & mass spec) |
$XX Million | $XX Million | XX% |
| Molecular – non-Infectious Disease |
$XX Million | $XX Million | XX% |
| POC Diabetes (all) | $XX Million | $XX Million | XX% |
| POC – Other | $XX Million | $XX Million | XX% |
| Immunoassay | $XX Million | $XX Million | XX% |
| Immunoassay Infectious Disease | $XX Million | $XX Million | XX% |
| Immunoassay non-Infectious | $XX Million | $XX Million | XX% |
| Coagulation | $XX Million | $XX Million | XX% |
| Histology | $XX Million | $XX Million | XX% |
| Hematology | $XX Million | $XX Million | XX% |
| Blood Typing | $XX Million | $XX Million | XX% |
| Others | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | XX% |
Source: Kalorama Information
